Loxo Oncology Inc (LOXO.OQ)
LOXO.OQ on NASDAQ Stock Exchange Global Market
159.27USD
21 Sep 2018
159.27USD
21 Sep 2018
Change (% chg)
$0.01 (+0.01%)
$0.01 (+0.01%)
Prev Close
$159.26
$159.26
Open
$158.93
$158.93
Day's High
$160.08
$160.08
Day's Low
$158.49
$158.49
Volume
397,107
397,107
Avg. Vol
145,572
145,572
52-wk High
$208.78
$208.78
52-wk Low
$71.45
$71.45
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 42.60 | -0.389 |
| Mar '18 | 38.43 | -0.119 | |
| FY 2017 | Dec '17 | 21.30 | -0.688 |
| Sep '17 | 0.00 | -2.454 | |
| Jun '17 | 0.00 | -1.143 | |
| Mar '17 | 0.00 | -0.956 | |
| FY 2016 | Dec '16 | 0.00 | -1.260 |
| Sep '16 | 0.00 | -0.819 | |
| Jun '16 | 0.00 | -0.773 | |
| Mar '16 | 0.00 | -0.593 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 8 | 37.80 | 50.00 | 0.00 | -- |
| Quarter Ending Dec-18 | 7 | 52.29 | 119.00 | 2.90 | -- |
| Year Ending Dec-18 | 6 | 177.47 | 250.00 | 84.00 | 33.54 |
| Year Ending Dec-19 | 6 | 166.02 | 259.00 | 15.60 | 128.78 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 8 | -0.89 | 0.00 | -1.90 | -- |
| Quarter Ending Dec-18 | 7 | -0.52 | 2.56 | -1.91 | -- |
| Year Ending Dec-18 | 5 | -1.83 | 2.05 | -4.33 | -4.38 |
| Year Ending Dec-19 | 7 | -4.63 | -2.38 | -10.35 | -3.16 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 108.33 | 32.69 | |
| P/E High - Last 5 Yrs. | -- | 278.75 | 47.23 | |
| P/E Low - Last 5 Yrs. | -- | 97.93 | 24.79 | |
| Beta | 2.22 | 0.61 | 0.87 | |
| Price to Sales (TTM) | 47.42 | 110.30 | 6.46 | |
| Price to Book (MRQ) | 12.36 | 12.48 | 3.90 | |
| Price to Tangible Book (MRQ) | 12.38 | 18.90 | 5.96 | |
| Price to Cash Flow (TTM) | -- | 62.41 | 23.20 | |
| % Owned Institutions | -- | 0.00 | 0.00 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.35 | 1.69 | |
| Dividend Yield - 5 Year Avg | -- | 0.21 | 1.45 | |
| Dividend 5 Year Growth Rate | -- | 2.62 | -5.70 | |
| Payout Ratio(TTM) | -- | 5.94 | 46.56 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 175.09 | 8.38 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 92.96 | 6.69 | |
| Sales - 5 Yr. Growth Rate | -- | 24.50 | 7.56 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 66.00 | 283.36 | 25.56 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 12.63 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 23.65 | 7.60 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 38.57 | 8.37 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.63 | 2.19 |
| Current Ratio (MRQ) | 3.64 | 5.49 | 2.97 |
| LT Debt to Equity (MRQ) | 0.00 | 15.10 | 11.24 |
| Total Debt to Equity (MRQ) | 0.00 | 18.62 | 14.06 |
| Interest Coverage (TTM) | -- | -215.83 | 35.11 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 56.03 | 54.67 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.71 | 53.30 | |
| EBITD Margin (TTM) | -114.07 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -177.00 | 15.88 | |
| Operating Margin (TTM) | -114.33 | -607.80 | 3.65 | |
| Operating Margin - 5 Yr. Avg. | -- | -190.63 | 11.00 | |
| Pre-Tax Margin (TTM) | -106.74 | -604.88 | 3.97 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -193.42 | 11.19 | |
| Net Profit Margin (TTM) | -106.74 | -599.69 | 0.70 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -191.17 | 7.52 | |
| Effective Tax Rate (TTM) | -- | 11.60 | 20.44 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 19.16 | 24.27 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 1,734,407 | 5,335,375 | 714,979,821 | |
| Net Income/Employee (TTM) | -1,851,373 | -5,831,664 | 82,568,832 | |
| Receivable Turnover (TTM) | -- | 4.20 | 5.01 | |
| Inventory Turnover (TTM) | -- | 2.06 | 3.61 | |
| Asset Turnover (TTM) | 0.17 | 0.38 | 0.82 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -18.37 | 0.80 | 9.75 | |
| Return on Assets - 5 Yr. Avg. | -- | 2.53 | 10.91 | |
| Return on Investment (TTM) | -22.03 | 1.50 | 12.72 | |
| Return on Investment - 5 Yr. Avg. | -- | 2.04 | 14.03 | |
| Return on Equity (TTM) | -25.60 | 0.19 | 14.85 | |
| Return on Equity - 5 Yr. Avg. | -- | -2.23 | 15.38 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -53.34 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Loxo Oncology Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- Bayer open for drug licensing deals, cutting debt remains priority
- Bayer open for drug licensing deals, cutting debt remains priority
- Loxo-Bayer cancer drug gets priority review from FDA
- Loxo-Bayer cancer drug gets priority review from FDA
- Loxo Oncology's targeted RET drug shows promise in early trial
Institutional Holders
| % Shares Owned: | 95.72% |
| # of Holders: | 312 |
| Total Shares Held: | 29,164,923 |
| 3 Mo. Net Change: | -2,755,060 |
| # New Positions: | 85 |
| # Closed Positions: | 13 |
| # Increased Positions: | 184 |
| # Reduced Positions: | 98 |
| # Net Buyers: | 86 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.